SELLAS Life Sciences Group (NASDAQ:SLS) Shares Up 8.5% – Should You Buy?

Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) rose 8.5% on Monday . The stock traded as high as $8.79 and last traded at $8.7310. Approximately 2,294,352 shares were traded during trading, a decline of 71% from the average session volume of 8,000,304 shares. The stock had previously closed at $8.05.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Maxim Group increased their price target on shares of SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Thursday, March 12th. Weiss Ratings restated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Tuesday, April 21st. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $10.00.

SELLAS Life Sciences Group Price Performance

The firm has a market cap of $1.70 billion, a price-to-earnings ratio of -37.63 and a beta of 2.50. The stock has a 50-day moving average price of $6.64 and a 200 day moving average price of $4.89.

SELLAS Life Sciences Group (NASDAQ:SLS) last announced its earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01.

Institutional Trading of SELLAS Life Sciences Group

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in SELLAS Life Sciences Group by 2.8% in the 3rd quarter. Vanguard Group Inc. now owns 6,839,905 shares of the company’s stock valued at $11,012,000 after acquiring an additional 185,106 shares during the period. Anson Funds Management LP lifted its holdings in shares of SELLAS Life Sciences Group by 2,093.8% during the third quarter. Anson Funds Management LP now owns 6,032,938 shares of the company’s stock worth $9,713,000 after purchasing an additional 5,757,938 shares during the period. Geode Capital Management LLC grew its position in SELLAS Life Sciences Group by 35.9% in the 4th quarter. Geode Capital Management LLC now owns 3,077,337 shares of the company’s stock valued at $11,604,000 after buying an additional 812,953 shares during the last quarter. Marshall Wace LLP grew its position in SELLAS Life Sciences Group by 23,550.0% in the 2nd quarter. Marshall Wace LLP now owns 2,715,489 shares of the company’s stock valued at $5,947,000 after buying an additional 2,704,007 shares during the last quarter. Finally, State Street Corp increased its stake in SELLAS Life Sciences Group by 60.8% in the 4th quarter. State Street Corp now owns 2,188,171 shares of the company’s stock valued at $8,249,000 after buying an additional 827,257 shares during the period. Hedge funds and other institutional investors own 17.38% of the company’s stock.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.